SUPPLEMENTAL MATERIAL TABLE OF CONTENTS

Supplemental Table: Associations of fast eGFR decline with subsequent frailty in the Multidomain Alzheimer Preventive Trial (sensitivity analyses #5 to 10)

Supplemental Table: Associations of fast eGFR decline with subsequent frailty in the Multidomain Alzheimer Preventive Trial (sensitivity analyses #5 to 10)

Definition of eGFR fast decline	N at risk / N events	Unadjusted HR (95% CI)	p	Adjusted HR (95% CI)	p
#5: More rapid than -4.1 mL/min/1.73m^2/y **Participants in the placebo group**	211 / 28	2.1 (0.97-4.57)	0.06	1.62 (0.65-4.05)	0.29
#6: More rapid than -4.1 mL/min/1.73m^2/y **Adjusted on mean eGFR instead of baseline eGFR**	833 / 95			1.56 (1.01-2.41)	0.045
#7: More rapid than -4.1 mL/min/1.73m^2/y **Adding death as a confounder**	833 / 95			1.67 (1.03-2.71)	0.04
#8: More rapid than -4.1 mL/min/1.73m^2/y **Model with an interaction term between study intervention group and fast eGFR decline**	833 / 95			2.13 (0.92-4.95)	0.08
#9: **Model with 3 groups according to eGFR slope quartiles:**					
Stable eGFR	833 / 95	Ref		Ref	
eGFR fast decline (more rapid than -4.1 ml/min/1.73m^2/y)		1.49 (0.94-2.37)	0.09	1.58 (0.95-2.62)	0.08
eGFR improvement (more rapid than 3.8 ml/min/1.73m^2/y)		0.94 (0.56-1.57)	0.81	0.81 (0.44-1.50)	0.51
#10: **eGFR slope as a continuous variable (per 1 ml/min/1.73 m^2/y decrease)**	833 / 95	1.00 (0.97-1.03)	0.88	1.01 (0.98-1.05)	0.51